Manufacturer discounts on branded drugs provided to Medicare Part D beneficiaries in the coverage gap may be more helpful in lowering costs if they are required in the catastrophic phase of the benefit, Medicare Payment Advisory Commission executive director James Mathews told a US House subcommittee on 30 April.
MedPAC is interested in the idea of shifting the 70% discount requirement to the catastrophic phase but has not yet...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?